{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:26:12Z","timestamp":1768699572684,"version":"3.49.0"},"reference-count":43,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Non-alcoholic steatohepatitis (NASH) is a major cause of chronic liver disease. However, most available animal models fail to reflect the whole spectrum of the disease. Liver fibrosis and portal hypertension are the strongest prognostic markers in advanced NASH. We herein aimed at developing a new model of NASH in male rats, obtained using a multi-hit protocol that combines the administration of a high fat and high-cholesterol diet with CCl4 and phenobarbital. Following this protocol, rats showed the full characteristics of advanced human NASH after 10 weeks and NASH with cirrhosis by 24 weeks. Specifically, our NASH rats exhibited: steatosis and metabolic syndrome, lipotoxicity, hepatocellular ballooning necrosis, inflammation and importantly, marked hepatic fibrosis and significant portal hypertension. Furthermore, a whole transcriptomic analysis of liver tissue from our rat model using next generation sequencing was compared with human NASH and illustrated the similarity of this pre-clinical model with the human disease. Pathway enrichment analysis showed that NASH animals shared a relevant number of central pathways involved in NASH pathophysiology, such as those related with cell death, as well as inflammatory or matrix remodeling. The present study defines a pre-clinical model of moderate and advanced NASH that mimics the human disease, including pathophysiologic characteristics and transcriptomic signature.<\/jats:p>","DOI":"10.3390\/cells8091062","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T10:52:26Z","timestamp":1568112746000},"page":"1062","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease"],"prefix":"10.3390","volume":"8","author":[{"given":"Raquel","family":"Maeso-D\u00edaz","sequence":"first","affiliation":[{"name":"Liver Vascular Biology Research Group, Barcelona Hepatic Hemodynamic Laboratory, IDIBAPS Biomedical Research Institute, CIBEREHD, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Boyer-Diaz","sequence":"additional","affiliation":[{"name":"Barcelona Liver Bioservices, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Lozano","sequence":"additional","affiliation":[{"name":"Bioinformatics Platform, CIBEREHD, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00ed","family":"Ortega-Ribera","sequence":"additional","affiliation":[{"name":"Liver Vascular Biology Research Group, Barcelona Hepatic Hemodynamic Laboratory, IDIBAPS Biomedical Research Institute, CIBEREHD, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Peralta","sequence":"additional","affiliation":[{"name":"Protective Strategies Against Hepatic Ischemia Reperfusion Injury Research Group, IDIBAPS & CIBEREHD, 08036, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Bosch","sequence":"additional","affiliation":[{"name":"Liver Vascular Biology Research Group, Barcelona Hepatic Hemodynamic Laboratory, IDIBAPS Biomedical Research Institute, CIBEREHD, 08036 Barcelona, Spain"},{"name":"Hepatology, Department of Biomedical Research, University of Bern, 3012 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-4089","authenticated-orcid":false,"given":"Jordi","family":"Gracia-Sancho","sequence":"additional","affiliation":[{"name":"Liver Vascular Biology Research Group, Barcelona Hepatic Hemodynamic Laboratory, IDIBAPS Biomedical Research Institute, CIBEREHD, 08036 Barcelona, Spain"},{"name":"Hepatology, Department of Biomedical Research, University of Bern, 3012 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"178","author":"Lazo","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/cld.709","article-title":"Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis","volume":"11","author":"Wegermann","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10620-015-3977-1","article-title":"Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame","volume":"61","author":"Ibrahim","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_6","unstructured":"Romestaing, C., Piquet, M.A., Bedu, E., Rouleau, V., Dautresme, M., Hourmand-Ollivier, I., Filippi, C., Duchamp, C., and Sibille, B. (2007). Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.nu.14.070194.001413","article-title":"Choline and Human Nutrition","volume":"14","author":"Zeisel","year":"1994","journal-title":"Annu. Rev. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3164\/jcbn.08-256","article-title":"Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis","volume":"44","author":"Nakamoto","year":"2009","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cgh.2012.05.008","article-title":"Prevalence and Indicators of Portal Hypertension in Patients With Nonalcoholic Fatty Liver Disease","volume":"10","author":"Mendes","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","first-page":"1019","article-title":"Animal models of portal hypertension","volume":"1565","author":"Brusilovskaya","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1440-1681.12102","article-title":"A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice","volume":"40","author":"Kubota","year":"2013","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1242\/dmm.002733","article-title":"Rats!","volume":"2","author":"Iannaccone","year":"2009","journal-title":"Dis. Model. Mech."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1098\/rstb.1985.0169","article-title":"Carbon tetrachloride toxicity as a model for studying free-radical mediated liver injury","volume":"311","author":"Slater","year":"1985","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pasar\u00edn, M., La Mura, V., Gracia-Sancho, J., Garc\u00eda-Calder\u00f3, H., Rodr\u00edguez-Vilarrupla, A., Garc\u00eda-Pag\u00e1n, J.C., Bosch, J., and Abraldes, J.G. (2012). Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS ONE.","DOI":"10.1371\/journal.pone.0032785"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1053\/j.gastro.2007.06.021","article-title":"Evidence Against a Role for NADPH Oxidase Modulating Hepatic Vascular Tone in Cirrhosis","volume":"133","author":"Brandes","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep4.1360","article-title":"Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism","volume":"3","author":"Manicardi","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.14336\/AD.2019.0127","article-title":"Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease","volume":"10","author":"Lafoz","year":"2019","journal-title":"Aging Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Maeso-D\u00edaz, R., Ortega-Ribera, M., Fern\u00e1ndez-Iglesias, A., Hide, D., Mu\u00f1oz, L., Hessheimer, A.J., Vila, S., Franc\u00e9s, R., Fondevila, C., and Albillos, A. (2018). Effects of aging on liver microcirculatory function and sinusoidal phenotype. Aging Cell.","DOI":"10.1111\/acel.12829"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","article-title":"KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: Behind the molecular mechanisms of statins","volume":"64","author":"Marrone","year":"2015","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2018.07.022","article-title":"Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension","volume":"155","author":"Tripathi","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2016.07.051","article-title":"Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury","volume":"66","author":"Vila","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, B., and Dewey, C.N. (2014). RSEM: Accurate transcript quantification from RNA-seq data with or without a reference genome. Bioinforma. Impact Accurate Quantif. Proteomic Genet. Anal. Res.","DOI":"10.1201\/b16589-5"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1101\/gr.1858004","article-title":"The Ensembl automatic gene annotation system","volume":"14","author":"Curwen","year":"2004","journal-title":"Genome Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ritchie, M., Phipson, B., Wu, D., Hu, Y., Law, C., Shi, W., and Smyth, G. (2015). limma powers di erential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res.","DOI":"10.1093\/nar\/gkv007"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05488","article-title":"Abdominal obesity and metabolic syndrome","volume":"444","author":"Lemieux","year":"2006","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, Y., Meyer, C., Xu, C., Weng, H., Hellerbrand, C., ten Dijke, P., and Dooley, S. (2012). Animal models of chronic liver diseases. Am. J. Physiol. Liver Physiol.","DOI":"10.1152\/ajpgi.00199.2012"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Nasr","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/lt.23646","article-title":"High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation","volume":"19","author":"Venu","year":"2013","journal-title":"Liver Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4161\/auto.19947","article-title":"Autophagy fuels tissue fibrogenesis","volume":"8","author":"Friedman","year":"2012","journal-title":"Autophagy"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Saeed, A., Dullaart, R.P.F., Schreuder, T.C.M.A., Blokzijl, H., and Faber, K.N. (2018). Disturbed vitamin A metabolism in non-alcoholic fatty liver disease (NAFLD). Nutrients, 10.","DOI":"10.3390\/nu10010029"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1872-034X.2010.00646.x","article-title":"Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease","volume":"40","author":"Ashla","year":"2010","journal-title":"Hepatol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11695-007-9361-2","article-title":"Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity","volume":"18","author":"Pereira","year":"2008","journal-title":"Obes. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/labinvest.2015.95","article-title":"Pivotal role of liver sinusoidal endothelial cells in NAFLD\/NASH progression","volume":"95","author":"Miyao","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Persico, M., Masarone, M., Damato, A., Ambrosio, M., Federico, A., Rosato, V., Bucci, T., Carrizzo, A., and Vecchione, C. (2017). Non alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterol.","DOI":"10.1186\/s12876-017-0592-y"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sanyal, A.J., Harrison, S.A., Ratziu, V., Abdelmalek, M.F., Diehl, A.M., Caldwell, S., Shiffman, M.L., Schall, R.A., Jia, C., and McColgan, B. (2019). The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials. Hepatology.","DOI":"10.1002\/hep.30664"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/9\/1062\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:18:37Z","timestamp":1760188717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/9\/1062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["cells8091062"],"URL":"https:\/\/doi.org\/10.3390\/cells8091062","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]}}}